BPC-157 10 mg + KPV 10 mg. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.
The studies behind this compound did not test timing or food state as variables, so we are not going to invent a rule. Pick a time you can keep to consistently.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Weeks 1–2 | 400 mcg | daily | 0.06 mL | 6 u | 14 | 5.6 mg |
| Weeks 3–4 | 600 mcg | daily | 0.09 mL | 9 u | 14 | 8.4 mg |
| Week 5 onward per 4 weeks from here on |
1000 mcg | daily | 0.15 mL | 15 u | 28 | 28 mg |
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial |
|---|---|---|---|---|---|
| Low reported | 400 mcg | 1× daily · 200 mcg of each compound | 0.06 mL | 6 u | 50 doses |
| Standard | 600 mcg | 1× daily · 300 mcg of each compound | 0.09 mL | 9 u | 33 doses |
| Upper reported | 1000 mcg | 1–2× daily · 500 mcg of each compound | 0.15 mL | 15 u | 20 doses |
An equal-parts repair and anti-inflammatory pairing — 10 mg of each in a 20 mg vial, so every dose splits evenly down the middle and a 600 mcg dose is 300 mcg apiece. Both components sit in the same 200–500 mcg daily range, which makes this an unusually well-matched blend: unlike most fixed-ratio combinations, neither one caps the other. Both are preclinical, with no human efficacy trials behind either.
Buy BPC-157 / KPV BlendPaid affiliate links.
Adding 3 mL of bacteriostatic water to a 20 mg vial gives 6.67 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.
Published and reported figures for BPC-157 / KPV Blend run from 400 mcg to 1000 mcg, typically 1× daily (200 mcg each). This site lists each figure with the source it came from rather than giving a single recommended number.
At 6.67 mg/mL, a 400 mcg dose is 6 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 50 doses.
BPC-157 / KPV Blend is graded preclinical. Laboratory and animal data only. No human dosing trials have been published. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.
Both are studied in gut models, which is the point of the pairing. BPC-157 has the larger preclinical record for gastrointestinal healing; KPV is studied for anti-inflammatory activity, with a good deal of that work in colitis models.
So the combination targets repair and inflammation in the same tissue, rather than two unrelated goals. Of all the blends here, this one has the clearest shared rationale.
Compounds in the same class, or browse the full catalogue.
A GHRH analogue paired with a selective ghrelin receptor agonist — the pairing rationale is that the two receptors act synergistic…
A fixed-ratio combination vial. Because the components are pooled at a fixed ratio, you cannot titrate one without moving the othe…
Every compound compared in one table: dose range, how often, half-life and evidence tier.
Need this on one page to print, screenshot or send?
Make a dose card →